Literature DB >> 3020677

Inhibition of erythropoiesis by human parvovirus-containing serum from a patient with hereditary spherocytosis in aplastic crisis.

M Takahashi, T Koike, Y Moriyama, A Shibata, R Koike, M Sanada, T Tsukada.   

Abstract

Aplastic phase serum from a patient with aplastic crisis of hereditary spherocytosis, which was demonstrated to contain human parvovirus, inhibited in vitro erythroid colony formation almost completely. Human parvovirus was resistant to heating for 30 min at 56 degrees C. The suppressive effect of the serum was completely abrogated by adding convalescent phase serum from another patient with aplastic crisis of hereditary spherocytosis. Some normal sera had similar neutralizing ability. The results suggested that aplastic crisis of a patient with hereditary spherocytosis is caused by human parvovirus and that the neutralizing test could offer a tool for predicting the future occurrence of aplastic crisis in the patients with chronic hemolytic anemia.

Entities:  

Mesh:

Year:  1986        PMID: 3020677     DOI: 10.1111/j.1600-0609.1986.tb01784.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  3 in total

1.  Serum erythropoietic inhibitors in patients with pure red cell aplasia.

Authors:  M Takahashi; K Nikkuni; I Tanaka; T Furukawa; Y Moriyama; A Shibata; S Satoh; Y Kuwabara; Y Maruyama; Y Matsunaga
Journal:  Ann Hematol       Date:  1991-07       Impact factor: 3.673

2.  Persistence of parvovirus B19-DNA in blood of a child with severe combined immunodeficiency associated with chronic pure red cell aplasia.

Authors:  M Gahr; A Pekrun; H Eiffert
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

Review 3.  Human parvovirus B19-induced aplastic crisis in an adult patient with hereditary spherocytosis: a case report and review of the literature.

Authors:  Yujin Kobayashi; Yoshihiro Hatta; Yusaku Ishiwatari; Hitoshi Kanno; Masami Takei
Journal:  BMC Res Notes       Date:  2014-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.